← Back to Search

Dermal Filler

Restylane Kysse for Lip Filler

N/A
Waitlist Available
Research Sponsored by Q-Med AB
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult males or non-pregnant, non-breastfeeding females, 22 years of age or older with both biological parents of full Chinese descent
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 8, 16, 24, 32, 40 and 48
Awards & highlights

Study Summary

This trial will test how well Restylane Kysse works in Chinese subjects to improve the appearance of fine lines and wrinkles.

Who is the study for?
This trial is for adults over 22, of full Chinese descent, who want lip augmentation and can understand English. They must be willing to follow the study rules and not be pregnant or breastfeeding. People with allergies to hyaluronic acid or certain proteins, recent facial procedures, permanent facial treatments, or those in another study within the last month cannot join.Check my eligibility
What is being tested?
The trial is testing Restylane Kysse's ability to enhance lip appearance in an open-label phase IV study. This means everyone knows they're getting this specific lip filler and its effects on aesthetics are being closely monitored post-marketing.See study design
What are the potential side effects?
While not explicitly listed here, common side effects of similar fillers include swelling, redness at injection sites, pain or tenderness in the lips, bruising, itching and possibly lumps or bumps where injected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 22 or older, not pregnant or breastfeeding, and both my parents are fully Chinese.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 8, 16, 24, 32, 40 and 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 8, 16, 24, 32, 40 and 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline/last injection on MLFS
Proportion of participants assessed as at least 1-point improvement from baseline on MLFS
Secondary outcome measures
Percentage of participants assessed as at least 1-point improvement from baseline on WAS
Percentage of participants assessed as at least improved on the GAIS

Trial Design

1Treatment groups
Experimental Treatment
Group I: Restylane KysseExperimental Treatment1 Intervention
Hyaluronic Acid

Find a Location

Who is running the clinical trial?

Q-Med ABLead Sponsor
80 Previous Clinical Trials
12,615 Total Patients Enrolled
Galderma R&DLead Sponsor
298 Previous Clinical Trials
60,280 Total Patients Enrolled
Study DirectorStudy DirectorGalderma R&D
1,207 Previous Clinical Trials
489,630 Total Patients Enrolled

Media Library

Restylane Kysse (Dermal Filler) Clinical Trial Eligibility Overview. Trial Name: NCT05342753 — N/A
Lip Filler Research Study Groups: Restylane Kysse
Lip Filler Clinical Trial 2023: Restylane Kysse Highlights & Side Effects. Trial Name: NCT05342753 — N/A
Restylane Kysse (Dermal Filler) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05342753 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor currently recruiting participants?

"As per information on clinicaltrials.gov, this experiment is now actively recruiting patients for participation; it was first posted in June 13th 2022 and the most recent update occurred August 24th of that year."

Answered by AI

How many participants are taking part in this research?

"Indeed, the particulars on clinicaltrials.gov attest that this trial is actively searching for applicants. The investigation was launched June 13th 2022 with a most recent update of August 24th and requires 50 participants at one medical facility."

Answered by AI
~15 spots leftby Jan 2025